Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transdermal nitroglycerin systems: methods for comparison.

L I Harrison1, D J Riedel

  • 1Department of Drug Metabolism, 3M Pharmaceuticals, St. Paul, Minnesota.

Clinical Therapeutics
|May 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is the Differentiated Service Delivery Model Suited to the Needs of People Living with HIV in Rwanda?

AIDS and behavior·2024
Same author

Rhodotorula glutinis fungemia in a liver-kidney transplant patient.

Transplant infectious disease : an official journal of the Transplantation Society·2007
Same author

Direct measurement of BDP and 17-BMP in bronchial and peripheral lung tissue after inhalation of HFA- vs CFC-driven aerosols.

Pulmonary pharmacology & therapeutics·2004
Same author

Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children.

Pediatric pulmonology·2003
Same author

Lung-to-systemic exposure ratio (L:S) calculation.

Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine·2001
Same author

Commentary on the FDA draft guidance for bioequivalence studies for nasal aerosols and nasal sprays for local action: an industry view.

Journal of clinical pharmacology·2000
Same journal

Early Feasibility Studies in Europe: A Multisite Qualitative Study of Operational Challenges and Site Selection Determinants at 6 University Hospitals.

Clinical therapeutics·2026
Same journal

Safety of Celecoxib in Elderly Patients With Osteoarthritis: A Real-World Analysis Based on the FAERS Database.

Clinical therapeutics·2026
Same journal

Reimagining Representation Across the Clinical Research Ecosystem: Part II of a Specialty Update on Advancing Diversity, Racial Equity, and Inclusion in Clinical Research.

Clinical therapeutics·2026
Same journal

Combined Effects of Nicorandil and Enhanced External Counterpulsation on Coronary Microcirculation and Exercise Capacity in Patients With Coronary Slow Flow Phenomenon: A Randomized, Controlled, 3-Arm Trial.

Clinical therapeutics·2026
Same journal

Phase 1 Study Evaluating Gefurulimab Pharmacokinetics and Safety Following Delivery Via Autoinjector or Prefilled Syringe With Needle Safety Device in Healthy Adults.

Clinical therapeutics·2026
Same journal

Evaluating Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Associated With Newer Antiseizure Medications Using FAERS and JADER Combined With Bioinformatics Exploration.

Clinical therapeutics·2026
See all related articles

Transdermal nitroglycerin systems offer sustained drug delivery, but plasma levels vary. Minitran showed superior adhesion and patient preference over other systems in clinical studies.

Area of Science:

  • Pharmacology
  • Drug Delivery Systems
  • Cardiology

Background:

  • Transdermal nitroglycerin systems aim for sustained drug delivery, maintaining therapeutic levels despite short elimination half-lives.
  • Significant variability in plasma drug levels across different transdermal systems complicates direct comparisons and clinical interpretation.
  • Clinical performance assessment extends beyond plasma levels to include adhesion and patient-reported outcomes.

Purpose of the Study:

  • To compare the clinical performance of Minitran against other transdermal nitroglycerin systems.
  • To evaluate adhesive properties and patient preference as key metrics for transdermal drug delivery efficacy.

Main Methods:

  • An adhesion study comparing Minitran to Transderm-Nitro, Nitro-Dur II, and a reference tape.

Related Experiment Videos

  • Patient preference studies involving hundreds of angina pectoris patients evaluating multiple system attributes.

    • Main Results:

    • Minitran exhibited superior adhesive properties compared to Transderm-Nitro and Nitro-Dur II.
    • Patients consistently preferred Minitran over Transderm-Nitro and Nitro-Dur II.
    • Key patient-cited advantages for Minitran included smaller size, better shape, ease of application, comfort, improved adhesion, and less skin irritation.

    Conclusions:

    • Minitran demonstrates enhanced clinical performance through superior adhesion and patient preference.
    • These findings suggest Minitran may offer a more effective and tolerable transdermal nitroglycerin option for angina management.
    • Adhesion and patient-reported outcomes are critical for evaluating transdermal system efficacy beyond plasma concentration data.